Lewis Mark C, Phillips Madeleine L, Slavotinek John P, Kow Lilian, Thompson Campbell H, Toouli Jim
Department of General and Digestive Surgery, Flinders Medical Centre, Flinders University of South Australia, Bedford Park, South Australia, Australia.
Obes Surg. 2006 Jun;16(6):697-701. doi: 10.1381/096089206777346682.
Laparoscopic adjustable gastric banding (LAGB) requires surgical access to the gastroesophageal junction, which may be compromised by the enlarged, fatty liver that is frequently encountered in the obese. Liver size appears reduced and surgical access improved following preoperative weight loss with Optifast Very Low Calorie Diet (VLCD). The aim of this study was to assess the effects of 6 weeks Optifast VLCD on liver volume and fat content.
18 morbidly obese subjects underwent magnetic resonance imaging and spectroscopy to measure liver size and fat content before and after intensive treatment with Optifast VLCD for 6 weeks.
All subjects completing 6 weeks Optifast VLCD lost weight. Body weight and BMI (median [interquartile range]) reduced from 119.7 [111.9-131.3] kg and 44 [40-51] kg/m(2) respectively, to 110.6 [98.0124.5] kg and 40 [36-47] kg/m(2), P<0.001. Median excess weight loss (EWL) was 15.1 [9.6-21.1]%. Baseline liver volume and fat content were related (r=0.633, P=0.005). After 6 weeks Optifast VLCD, there was a 14.7% reduction in mean liver volume (P<0.001) and a 43% reduction in mean liver fat (P=0.016). The change in liver volume was predicted by the change in the liver fat (r = 0.610, P=0.012).
This study has demonstrated that a 6 week diet with Optifast VLCD results in significant related reductions in liver size and liver fat content. This suggests that the reduction in liver volume is due to loss of fat. The reduction in liver fat and volume likely accounts for the perceived improved operability in patients undergoing LAGB.
腹腔镜可调节胃束带术(LAGB)需要手术进入胃食管交界处,而肥胖患者常见的肝脏肿大和脂肪肝可能会影响手术操作。采用Optifast极低热量饮食(VLCD)进行术前减重后,肝脏大小似乎减小,手术操作空间得到改善。本研究的目的是评估Optifast VLCD 6周对肝脏体积和脂肪含量的影响。
18例病态肥胖受试者在接受Optifast VLCD强化治疗6周前后,接受磁共振成像和波谱分析以测量肝脏大小和脂肪含量。
所有完成6周Optifast VLCD治疗的受试者均体重减轻。体重和体重指数(中位数[四分位间距])分别从119.7 [111.9 - 131.3] kg和44 [40 - 51] kg/m²降至110.6 [98.0 - 124.5] kg和40 [36 - 47] kg/m²,P < 0.001。平均超重减轻(EWL)中位数为15.1 [9.6 - 21.1]%。基线肝脏体积与脂肪含量相关(r = 0.633,P = 0.005)。Optifast VLCD治疗6周后,平均肝脏体积减少14.7%(P < 0.001),平均肝脏脂肪减少43%(P = 0.016)。肝脏体积的变化可由肝脏脂肪的变化预测(r = 0.610,P = 0.012)。
本研究表明,Optifast VLCD 6周饮食可使肝脏大小和肝脏脂肪含量显著相关降低。这表明肝脏体积的减小是由于脂肪减少。肝脏脂肪和体积的减少可能是接受LAGB手术患者手术可操作性改善的原因。